二氯亚甲基二膦酸盐（Cl2MDP）对骨佩吉特病的生化及临床反应

Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget's disease of bone.

作者信息

Douglas D L, Duckworth T, Kanis J A, Preston C, Beard D J, Smith T W, Underwood I, Woodhead J S, Russell R G

出版信息

Arthritis Rheum. 1980 Oct;23(10):1185-92. doi: 10.1002/art.1780231017.

Abstract

Dichloromethylene diphosphonate (Cl2MDP, or clodronate disodium) is one of the most potent of the known diphosphonates as an inhibitor of bone resorption and differs from EHDP in that it does not inhibit skeletal mineralization. It is one of the second generation diphosphonates now undergoing clinical evaluation. In the study described here Cl2MDP was given by mouth (800-1600 mg/day for 6 months) to 35 patients with symptomatic Paget's disease of bone. Cl2MDP induced a marked fall in serum alkaline phosphatase and urinary hydroxyproline to normal or near normal values in all patients. This was accompanied by clinical improvement in all but 4 patients. Cl2MDP appears to be another effective oral drug for the treatment of Paget's disease of bone and compares favorably with the calcitonins and EHDP.

摘要

二氯亚甲基二膦酸盐（Cl2MDP，或氯膦酸二钠）是已知的双膦酸盐中抑制骨吸收作用最强的药物之一，它与依替膦酸二钠（EHDP）的不同之处在于它不抑制骨骼矿化。它是目前正在进行临床评估的第二代双膦酸盐之一。在本文所述的研究中，35例有症状的骨Paget病患者口服Cl2MDP（800 - 1600毫克/天，持续6个月）。Cl2MDP使所有患者的血清碱性磷酸酶和尿羟脯氨酸显著下降至正常或接近正常水平。除4例患者外所有患者均有临床改善。Cl2MDP似乎是治疗骨Paget病的另一种有效口服药物，与降钙素和EHDP相比具有优势。